In the latest trading session, 0.44 million Cognition Therapeutics Inc (NASDAQ:CGTX) shares changed hands as the company’s beta touched 1.36. With the company’s most recent per share price at $0.52 changing hands around $0.04 or 8.44% at last look, the market valuation stands at $21.00M. CGTX’s current price is a discount, trading about -467.31% off its 52-week high of $2.95. The share price had its 52-week low at $0.34, which suggests the last value was 34.62% up since then. When we look at Cognition Therapeutics Inc’s average trading volume, we note the 10-day average is 0.31 million shares, with the 3-month average coming to 1.12 million.
Analysts gave the Cognition Therapeutics Inc (CGTX) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.33. If we narrow down to specifics, the data shows that 0 out of 3 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended CGTX as a Hold, 3 felt it is a Buy and 0 rated the stock as Underweight. Cognition Therapeutics Inc’s EPS for the current quarter is expected to be -0.21.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Cognition Therapeutics Inc (NASDAQ:CGTX) trade information
Instantly CGTX is in green as seen in intraday trades today. With action 16.84%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -71.72%, with the 5-day performance at 16.84% in the green. However, in the 30-day time frame, Cognition Therapeutics Inc (NASDAQ:CGTX) is 7.17% up. Looking at the short shares, we see there were 0.53 million shares sold at short interest cover period of 1.04 days.
Cognition Therapeutics Inc (CGTX) estimates and forecasts
Data shows that the Cognition Therapeutics Inc share is performing relatively much not better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -73.71% over the past 6 months, a -11.63% in annual growth rate that is considerably lower than the industry average of 17.40%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -21.09%. The 2024 estimates are for Cognition Therapeutics Inc earnings to increase by 4.07%.
CGTX Dividends
Cognition Therapeutics Inc is expected to release its next quarterly earnings report on 2024-Aug-08.
Cognition Therapeutics Inc (NASDAQ:CGTX)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 0.56% of Cognition Therapeutics Inc shares while 28.18% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 28.34%. There are 28.18% institutions holding the Cognition Therapeutics Inc stock share, with VANGUARD GROUP INC the top institutional holder. As of 2024-06-30, the company held 3.4016% of the shares, roughly 1.15 million CGTX shares worth $1.9 million.
AWM INVESTMENT COMPANY, INC. holds the second largest percentage of outstanding shares, with 1.9268% or 0.65 million shares worth $1.08 million as of 2024-06-30.
Among Mutual Funds, the top two as of Jun 30, 2024 were Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund. With 914.9 shares estimated at $0.48 million under it, the former controlled 2.28% of total outstanding shares. On the other hand, Vanguard Extended Market Index Fund held about 0.50% of the shares, roughly 200.58 shares worth around $0.1 million.
